CBMNet: The ‘Crossing Biological Membranes’ Network in Industrial Biotechnology and Bioenergy

The ∼1300 academic and industry members of the BBSRC (Biotechnology and Biological Sciences Research Council) Network in Industrial Biotechnology and Bioenergy (NIBB) Crossing Biological Membranes Network (CBMNet) are motivated to explore how knowledge of the roles of biological membranes can be exploited to enhance the productivity of cell factories. Improving existing, and developing new, cell factories requires a deep understanding of the mechanisms by which substances are transported into, within, and out of the cells. Embedding consideration of membrane function into the design of cell factories is crucial for the future of almost all cell-based Industrial Biotechnology and Bioenergy (IBBE) applications. CBMNet provides a forum for: knowledge exchange between academics and companies; developing new interactions in the context of responsible innovation; forming, and then supporting, new multi-disciplinary teams to develop innovative membrane-based solutions to overcome IBBE bottlenecks; and funding consortia to carry out feasibility studies with the target of generating competitive bids for further research funding. More broadly, CBMNet is working with other NIBB to raise the profile of IBBE among policymakers and develop a national strategy for IBBE in the U.K

Health-related quality of life in multiple sclerosis: Effects of natalizumab

Objective: To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab. Methods: HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study, patients received interferon beta-la (IFN-\u3b2-1a) plus natalizumab 300mg (n = 589), or IFN-\u3b2-1a plus placebo (n = 582). The Short Form-36 (SF-36) and a subject global assessment visual analog scale were administered at baseline and weeks 24, 52, and 104. Prespecified analyses included changes from baseline to week 104 in SF-36 and visual analog scale scores. Odds ratios for clinically meaningful improvement or worsening on the SF-36 Physical Component Summary (PCS) and Mental Component Summary were calculated. Results: Mean baseline SF-36 scores were significantly less than the general US population and correlated with Expanded Disability Status Scale scores, sustained disability progression, relapse number, and increased volume of brain magnetic resonance imaging lesions. Natalizumab significantly improved SF-36 PCS and Mental Component Summary scores at week 104 in AFFIRM. PCS changes were significantly improved by week 24 and at all subsequent time points. Natalizumab-treated patients in both studies were more likely to experience clinically important improvement and less likely to experience clinically important deterioration on the SF-36 PCS. The visual analog scale also showed significantly improved HRQoL with natalizumab. Interpretation: HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab. \ua9 2007 American Neurological Association. Published by Wiley-Liss, Inc